Literature DB >> 9127546

Sister Elizabeth Kenny, an Australian nurse, and treatment of poliomyelitis victims.

S R Oppewal1.   

Abstract

PURPOSE: To analyze the strategies that Elizabeth Kenny, an Australian nurse, used when trying to obtain medical endorsement for an innovation that was not based on knowledge of pathology, but was empirically demonstrated. SIGNIFICANCE: When faced with the need to "Do the best you can with the symptoms presenting themselves," Kenny used keen observation to develop a new treatment for poliomyelitis in the early 1900s. Her innovation was to use hot packs to relieve muscle spasms in people with early symptoms of poliomyelitis when orthodox medical treatment included use of splints or casts to immobilize affected limbs.
METHOD: Historical case analysis. FINDINGS AND
CONCLUSIONS: Sister Kenny made bold assertions, obtained scientific validation, learned from experience, used publicity, and opposed resistance. Although some strategies were unsuccessful (and Kenny faced many obstacles) medical practice changed in a relatively short time. Immobilization of limbs was largely discontinued in the acute stage of the disease. Kenny persisted in caring for children who otherwise might have sustained deformities.

Entities:  

Mesh:

Year:  1997        PMID: 9127546     DOI: 10.1111/j.1547-5069.1997.tb01145.x

Source DB:  PubMed          Journal:  Image J Nurs Sch        ISSN: 0743-5150


  2 in total

1.  Poliomyelitis: historical facts, epidemiology, and current challenges in eradication.

Authors:  Man Mohan Mehndiratta; Prachi Mehndiratta; Renuka Pande
Journal:  Neurohospitalist       Date:  2014-10

2.  Lower temperatures reduce type I interferon activity and promote alphaviral arthritis.

Authors:  Natalie A Prow; Bing Tang; Joy Gardner; Thuy T Le; Adam Taylor; Yee S Poo; Eri Nakayama; Thiago D C Hirata; Helder I Nakaya; Andrii Slonchak; Pamela Mukhopadhyay; Suresh Mahalingam; Wayne A Schroder; William Klimstra; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2017-12-27       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.